Skip to main content
OpenTrials
Completed

NCT Number: NCT06674018

Indole-3-PROpionic Acid Clinical Trials - a Pilot Study

The goal of this pilot intervention trial is to investigate the biological effects of daily supplementation with different doses of indole-3-propionic acid (IPA) in healthy adults. The main scientific questions are:

* Does supplementation with IPA increase the abundance regulatory T cells in the blood? Regulatory T cells are believed to play an important role in preventing autoimmune diseases. * Does supplementation with IPA increase the concentration of brain-derived neurotrophic factor (BDNF) in the blood? BDNF is believed to play an important role in maintaining brain health. * Does supplementation with IPA affect blood analyses commonly performed to assess the risk of metabolic disorders like type 2 diabetes and cardiovascular diseases? * How big a dose of IPA is necessary to achieve the above benefits?

Participants will:

* Take 50 mg IPA or 120 mg IPA or 500 mg IPA or placebo every morning for 14 days. * Visit the clinic at the beginning (day 1) and at the end (day 15) of IPA supplementation to deliver blood, urine and fecal samples, have simple measurements performed, fulfil questionnaires and report any side effects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Optic Neuritis Clinic, Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet-Glostrup

Glostrup Municipality, 2600, Denmark

About this study

Indole-3-propionic acid (IPA) is a gut bacterial metabolite with the amino acid tryptophan as substrate. In vitro and animal studies, suggest that IPA could contribute to regulating inflammation and metabolic function, preventing oxidative damage and upregulating expression of brain-derived neurotrophic factor. With this study we aim to investigate the biochemical effects of IPA at supraphysiological levels in humans.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy women and men ≥18 and ≤65 years of age
  • Deemed mentally and physically able to participate

Exclusion criteria

  • Diagnosis of gut-, heart-, liver-, kidney or immune-related disorders
  • Use of antibiotics within the last month
  • Pregnant or lactating women or birth within the last five months
  • Use of medicine that requires prescription

Treatment and study plan

Indole-3-propionic acid

Dietary Supplement

A dosis of either 50 mg IPA, 120 mg IPA or 500 mg IPA (two capsules) will be taken orally, once daily in the morning after an overnight fast for 14 consecutive days.

Placebo

Dietary Supplement

Two capsules of placebo will be taken orally, once daily in the morning after an overnight fast for 14 consecutive days.

Primary outcomes

  1. Regulatory T cells (first primary outcome)

    Time frame: Results from fasting blood samples taken on day 15 and adjusted for results from day 1 (fasting just before first supplement/placebo dosis).

    FoxP3+CD25+CD127- regulatory T cells expressed as a percentage of single, live CD3+CD4+CD8- lymphocytes. Analysed in freshly isolated peripheral blood mononuclear cells using a Symphony A3 flowcytometer.

  2. Brain-derived neurotrophic factor (second primary outcome)

    Time frame: Results from fasting blood samples taken on day 15 and adjusted for results from day 1 (fasting just before first supplement/placebo dosis).

    Brain-derived neurotrophic factor measured in plasma samples using ELISA or mesoscale.

Secondary outcomes

  1. Flowcytometric profiling of T cells

    Time frame: Results from fasting blood samples taken on day 15 and adjusted for results from day 1 (fasting just before first supplement/placebo dosis).

    T cell profiling of freshly isolated peripheral blood mononuclear cells using a Symphony A3 flowcytometer. Panel antigens: CD3, CD4, CD8, CD45RA, CCR7, CXCR3, CCR6, CCR4, CCR10, CD25, CD127, FoxP3.

    Target populations Th1: CXCR3+CCR4-CCR6-CCR10- Th2: CXCR3-CCR4+CCR6-CCR10- Th17: CXCR3-CCR4+CCR6+CCR10- Th17.1: CXCR3+CCR4-CCR6+CCR10- Th22: CXCR3-CCR4+CCR6+CCR10+ all of the above expressed as a percentage of single, live CD3+CD4+CD8-CD45RA- lymphocytes.

    Furthermore, Th1/Th2 and Th17/Treg ratios will be calculated and the expression of CCR7 will be analysed within the target populations.

    In addition, the expression of the above chemokine receptors will be explored within the population of FoxP3+CD25+C1D127- T regulatory cells. This will allow for monitoring of newly identified T cells subsets such as Th1-like Tregs.

    Lastly, an untargetted approach may be employed to allow for unbiased identification of changes in novel, yet uncharacterized populations.

  2. CRP

    Time frame: Results from blood samples taken on day 15 (just before last supplement/placebo dosis) and adjusted for results from day 1 (just before first supplement/placebo dosis).

    C-reactive protein (CRP) measured in plasma (mg/L) as a biomarker of infection and systemic inflammation. Lower-limit of quantification: 0,4 mg/L. Values below 0,4 mg/L are imputed as 0,2 mg/L.

  3. Triglycerides

    Time frame: Results from fasting blood samples taken on day 15 and adjusted for results from day 1 (fasting just before first supplement/placebo dosis).

    Plasma triglycerides (mmol/l).

  4. non-HDL cholesterol

    Time frame: Results from fasting blood samples taken on day 15 and adjusted for results from day 1 (fasting just before first supplement/placebo dosis).

    Non-HDL cholesterol calculated as total cholesterol minus HDL cholesterol (mmol/l)

  5. C-peptide

    Time frame: Results from fasting blood samples taken on day 15 and adjusted for results from day 1 (fasting just before first supplement/placebo dosis).

    Proinsulin C-peptide (pmol/l) measured in plasma.

  6. Fasting glucose

    Time frame: Results from fasting blood samples taken on day 15 and adjusted for results from day 1 (fasting just before first supplement/placebo dosis).

    Plasma glucose (mmol/l). Participants abstain from eating and drinking after 22.00 the day before. Only water is allowed. Fasting blood samples are taken between 8.00-10.00 in the morning.

  7. Isoprostane-F2-alpha

    Time frame: Results from samples taken on day 15 and adjusted for results from day 1.

    Isoprostane-F2-alpha measured in blood or morningurine samples as a marker of lipid oxidation.

  8. 8-oxo-dG

    Time frame: Results from samples taken on day 15 and adjusted for results from day 1.

    8-oxo-dG (8-Oxo-2'-deoxyguanosine) measured in blood or morningurine samples as a marker of DNA-related stress damage.

  9. Serum metabolomics

    Time frame: Four samples in total. Day 1 prior to and again 1.5 hour after intake of first capsule of IPA/ placeblo. Day 15 prior to and again 1.5 hour after intake of last capsule of IPA/ placebo.

    Targetted and untargetted liquid-chromatography mass-spectrometry-based metabolomics of serum samples. Targetted analyses aim to quantify indole-3-propionic acid and its metabolites (biomarker of compliance as well as absorptive and metabolic capacity), other bacterial- and host metabolites of tryptophan as well as short-chain fatty acids.

  10. Total cholesterol

    Time frame: Results from fasting blood samples taken on day 15 and adjusted for results from day 1 (fasting just before first supplement/placebo dosis).

    Plasma cholesterol (mmol/l).

  11. VLDL cholesterol

    Time frame: Results from fasting blood samples taken on day 15 and adjusted for results from day 1 (fasting just before first supplement/placebo dosis).

    Plasma very low-density lipoproteins (mmol/l).

  12. LDL cholesterol

    Time frame: Results from fasting blood samples taken on day 15 and adjusted for results from day 1 (fasting just before first supplement/placebo dosis).

    Plasma low-density lipoprotein (LDL) (mmol/l).

  13. HDL cholesterol

    Time frame: Results from fasting blood samples taken on day 15 and adjusted for results from day 1 (fasting just before first supplement/placebo dosis).

    Plasma high-density lipoprotein (HDL) (mmol/l).

  14. Malondialdehyde

    Time frame: Results from samples taken on day 15 and adjusted for results from day 1.

    Malondialdehyde measured in blood or morningurine samples as a marker of oxidative stress.

  15. Protein carbonyls

    Time frame: Results from samples taken on day 15 and adjusted for results from day 1.

    Protein carbonyls measured in blood or morningurine samples as a marker of protein oxidation.

  16. Glycated hemoglobin (HbA1c)

    Time frame: Results from fasting blood samples taken on day 15 and adjusted for results from day 1 (fasting just before first supplement/placebo dosis).

    HbA1c (IFCC, mmol/mol) measured in whole blood. Estimated average glucose values (mmol/l) are also calculated automatically from HbA1c by our laboratory.

  17. Changes in the gut microbiome

    Time frame: Fecal samples are collected at three time points: prior to supplementation (earliest 48 hours prior to first visit (day 1)), short after initiation of supplementation (day 3 or soonest thereafter) and again earliest 48 hours prior to last visit.

    Characterization of the gut microbiome using molecular biology methods such as 16s rRNA sequencing.

  18. Characterization of the metabolic activity of the gut microbiota

    Time frame: Fecal samples are collected at three time points: prior to supplementation (earliest 48 hours prior to first visit (day 1)), short after initiation of supplementation (day 3 or soonest thereafter) and again earliest 48 hours prior to last visit.

    Targetted and untargetted liquid-chromatography mass-spectrometry-based metabolomics. Targetted analyses aim to quantify indole-3-propionic acid, other bacterial- and host metabolites of tryptophan as well as short-chain fatty acids.

  19. Bacterial polysaccharides

    Time frame: Results from samples taken on day 15 and adjusted for results from day 1.

    Endotoxin, capsular polysaccharides or other bacterial polysaccharides measured in blood samples as biomarker of bacterial translocation across the intestinal epithelium.

  20. Pre-haptoglobin 2

    Time frame: Results from samples taken on day 15 and adjusted for results from day 1.

    Measurement of pre-haptoglobin 2 in blood samples as a biomarker of intestinal permeability.

  21. Intestinal fatty acid binding protein

    Time frame: Results from samples taken on day 15 and adjusted for results from day 1.

    Measurements of intestinal fatty acid binding protein in blood samples as a biomarker of enterocyte damage.

  22. Citrulline

    Time frame: Results from samples taken on day 15 and adjusted for results from day 1.

    Measurement of citrulline in blood samples as a biomarker of intestinal function.

  23. Calprotectin

    Time frame: Results from samples taken on day 15 and adjusted for results from day 1.

    Calprotectin measured in fecal samples as a biomarker of intestinal inflammation.

  24. Neopterin

    Time frame: Results from samples taken on day 15 and adjusted for results from day 1.

    Neopterin measured in morningurine samples as a biomarker of systemic inflammation.

  25. suPAR

    Time frame: Results from samples taken on day 15 and adjusted for results from day 1.

    Soluble urokinase plasminogen activator receptor (suPAR) measured in blood samples.

  26. Microvesicles

    Time frame: Results from samples taken on day 15 and adjusted for results from day 1.

    Flow cytometric analyses of microvesicles/ microparticles in platelet-free plasma as biomarker of systemic inflammation.

  27. Endothelial progenitor cells

    Time frame: Results from samples taken on day 15 and adjusted for results from day 1.

    Flow cytometric analyses of endothelial progenitor cells measured in platelet-free plasma as biomarker of systemic inflammation

Other outcomes

  1. Gastrointestinal comfort

    Time frame: Gastrointestinal symptoms are assessed on day 1 and day 15.

    Self-reported (questionnaire) gastrointestinal symptoms of bloating, pain, rumbling, flatulence, constipation, hard stools and diarrhea evaluated using a visual analogue scale as well as a question on the frequency of defecation.

  2. Gastrointestinal transit time

    Time frame: Maize is ingested five days before visit 1 and again five days before visit 2.

    Measurement of transit time through the digestive system using a so-called maize test. Participants consume 100 grams of sweet maize in the morning between 5.30-10.00 while still in a fasting state. The exact date and time of consumption is registered and so is the exact date and time when maize is observed for the first time in feces. Transit time is expressed as the difference between the ingestion and fecal excretion timepoints in hours.

  3. Stool consistency

    Time frame: Bristol stool chart is used in association with each maize test and collection of fecal samples (earliest 48 hours prior to first visit and day 3 or soonest thereafter and again earliest 48 hours prior to last visit (day 15)).

    Classification of stool consistency using the Bristol Stool Chart. Numerical scale ranging from 1 (separate hard lumps) to 7 (liquid consistency with no solid pieces) with one-unit increments.

  4. Fecal pH

    Time frame: Fecal samples are collected at three time points: prior to supplementation (earliest 48 hours prior to first visit (day 1)), short after initiation of supplementation (day 3 or soonest thereafter) and again earliest 48 hours prior to last visit (day 15).

    pH of collected fecal samples

  5. Antibody-coating of bacteria

    Time frame: Fecal samples are collected at three time points: prior to supplementation (earliest 48 hours prior to first visit (day 1)), short after initiation of supplementation (day 3 or soonest thereafter) and again earliest 48 hours prior to last visit (day 15).

    Characterization of IgA, IgG and IgM-coating of bacteria from fecal samples using bacterial flow cytometry.

  6. Immunoglobulin G

    Time frame: Results from fasting blood samples taken on day 15 and adjusted for results from day 1 (just before first supplement/placebo dosis).

    Plasma immunoglobulin G (g/l)

  7. Immunoglobulin A

    Time frame: Results from blood samples taken on day 15 (just before last supplement/placebo dosis) and adjusted for results from day 1 (just before first supplement/placebo dosis).

    Plasma immunoglobulin A (g/l)

  8. Leucocyte counts

    Time frame: Results from fasting blood samples taken on day 15 and adjusted for results from day 1 (just before first supplement/placebo dosis).

    Total leucocytes as well as basophils, eosinophils, lymphocytes, monocytes, neutrophils as well as the joint group of metamyelo-, myelo- and promyelocytes. All counted in whole blood samples (10^9/l).

  9. Hemoglobin

    Time frame: Results from blood samples taken on day 15 (just before last supplement/placebo dosis) and adjusted for results from day 1 (just before first supplement/placebo dosis).

    Hemoglobin measured in whole blood (mmol/l).

  10. Alanine transaminase

    Time frame: Results from fasting blood samples taken on day 15 and adjusted for results from day 1 (fasting just before first supplement/placebo dosis).

    Plasma alanine transaminase (ALT, U/l) as a biomarker of liver function.

  11. Alkaline phosphatase

    Time frame: Results from blood samples taken on day 15 (just before last supplement/placebo dosis) and adjusted for results from day 1 (just before first supplement/placebo dosis).

    Alkaline phosphatase (U/l) as a biomarker of liver function.

  12. Aspartate aminotransferase

    Time frame: Results from blood samples taken on day 15 (just before last supplement/placebo dosis) and adjusted for results from day 1 (just before first supplement/placebo dosis).

    Aspartate aminotransferase also known as aspartate transaminase measured in plasma (U/l) as a biomarker of liver damage.

  13. Bilirubin

    Time frame: Results from blood samples taken on day 15 (just before last supplement/placebo dosis) and adjusted for results from day 1 (just before first supplement/placebo dosis).

    Bilirubins measured in plasma (µmol/L) as a biomarker of liver function.

  14. Coagulation factors II + VII + X

    Time frame: Results from blood samples taken on day 15 (just before last supplement/placebo dosis) and adjusted for results from day 1 (just before first supplement/placebo dosis).

    Coagulation factors II + VII + X (INR: International Normalized Ratio) measured in plasma as a biomarker of liver function.

  15. Lactate dehydrogenase (LDH)

    Time frame: Results from blood samples taken on day 15 (just before last supplement/placebo dosis) and adjusted for results from day 1 (just before first supplement/placebo dosis).

    Lactate dehydrogenase measured in plasma (U/l).

  16. Creatinine

    Time frame: Results from blood samples taken on day 15 (just before last supplement/placebo dosis) and adjusted for results from day 1 (just before first supplement/placebo dosis)

    Plasma creatinine (µmol/L) as a biomarker of kidney function.

  17. eGFR

    Time frame: Results from blood samples taken on day 15 (just before last supplement/placebo dosis) and adjusted for results from day 1 (just before first supplement/placebo dosis).

    Estimated glomerular filtration rate (eGFR/ 1,73m² (ml/min)) as a biomarker of kidney function.

  18. Albumin

    Time frame: Results from blood samples taken on day 15 (just before last supplement/placebo dosis) and adjusted for results from day 1 (just before first supplement/placebo dosis).

    Albumin measured in plasma (g/l).

  19. 25-OH-vitamin D

    Time frame: Results from blood samples taken on day 15 (just before last supplement/placebo dosis) and adjusted for results from day 1 (just before first supplement/placebo dosis).

    Plasma 25-OH-vitamin D (D3+D2) (nmol/L)

  20. Blood pressure

    Time frame: Measured on day 1 and then again on day 15

    Blood pressure (mm Hg) defined as the lowest value obtained across three measurements.

Sponsors and collaborators

Lead sponsor

Glostrup University Hospital, Copenhagen

Other

Collaborators

  • University of Copenhagen
  • University of Southampton

Registry information

Official study title

Indole-3-PROpionic Acid Clinical Trials - a Pilot Study (iPROACT-pilot)

Acronym: iPROACT-pilot

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Nov 5, 2024
Registry last updated
Mar 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.